| Home > Institute Collections > W500 > Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium. |
| Journal Article | DKFZ-2025-02510 |
; ; ; ; ; ;
2025
Molecular Diversity Preservation International
Basel
Abstract: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative approach for cancer treatment, demonstrating remarkable success in patients with relapsed and refractory hematological malignancies. However, challenges persist in optimizing CAR-T cell production and improving therapeutic outcomes. One of the major hurdles is the efficiency of retroviral or lentiviral transduction during CAR-T cell manufacturing. Additionally, the heterogeneity of T-cell populations isolated from patients can impact CAR-T cell effectiveness and persistence in vivo. This article explores a novel strategy to address these challenges by focusing on serum-free medium and additive optimization. We propose a unique approach that incorporates the culturing of T cells in Nutri-T medium, along with 24 h of exposure to combined low concentrations of BX795 and rosuvastatin, to enhance the transduction efficacy and functionality of CAR-T cells. The results presented here provide promising insights into the potential of this strategy to produce more effective CAR-T cells for immunotherapy, ultimately advancing the field and benefiting cancer patients worldwide.
Keyword(s): Humans (MeSH) ; Rosuvastatin Calcium: pharmacology (MeSH) ; Receptors, Chimeric Antigen: metabolism (MeSH) ; Receptors, Chimeric Antigen: immunology (MeSH) ; Receptors, Chimeric Antigen: genetics (MeSH) ; Immunotherapy, Adoptive: methods (MeSH) ; T-Lymphocytes: drug effects (MeSH) ; T-Lymphocytes: immunology (MeSH) ; T-Lymphocytes: metabolism (MeSH) ; Culture Media, Serum-Free: pharmacology (MeSH) ; BX795 ; CAR-T ; Nutri-T ; PBMCs ; lentivirus ; rosuvastatin ; Rosuvastatin Calcium ; Receptors, Chimeric Antigen ; Culture Media, Serum-Free
|
The record appears in these collections: |